Nuveen Asset Management, LLC Inozyme Pharma, Inc. Transaction History

Nuveen Asset Management, LLC

$340 Billion
Q4 2024

A detailed history of Nuveen Asset Management, LLC transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 250,229 shares of INZY stock, worth $1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

250,229

Previous 202,729 23.43%

Holding current value

$1 Million

Previous $1.06 Million 34.62%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$2.48 - $5.54 $117,800 - $263,150	47,500 Added 23.43%	250,229 $693,000
Q3 2024 Nov 14, 2024	BUY	$4.31 - $6.0 $180,373 - $251,100	41,850 Added 26.01%	202,729 $1.06 Million
Q4 2023 Feb 14, 2024	BUY	$2.71 - $4.5 $62,682 - $104,085	23,130 Added 16.79%	160,879 $685,000
Q2 2023 Aug 14, 2023	BUY	$4.93 - $6.74 $679,102 - $928,428	137,749 New	137,749 $767,000
Q2 2022 Aug 15, 2022	SELL	$3.2 - $5.96 $139,436 - $259,701	-43,574 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.87 - $7.55 $5,081 - $9,913	1,313 Added 3.11%	43,574 $172,000
Q4 2021 Feb 14, 2022	SELL	$5.58 - $11.5 $30,137 - $62,111	-5,401 Reduced 11.33%	42,261 $251,000
Q3 2021 Nov 12, 2021	BUY	$11.12 - $19.4 $2,980 - $5,199	268 Added 0.57%	47,662 $565,000
Q2 2021 Aug 16, 2021	BUY	$15.19 - $21.2 $396,489 - $553,362	26,102 Added 122.59%	47,394 $808,000
Q4 2020 Feb 16, 2021	BUY	$19.95 - $27.55 $84,228 - $116,316	4,222 Added 24.73%	21,292 $439,000
Q3 2020 Nov 16, 2020	BUY	$17.54 - $30.2 $299,407 - $515,514	17,070 New	17,070 $449,000

Others Institutions Holding INZY

# of Institutions

Shares Held

4.86M

Call Options Held

Put Options Held

View Full List

About Inozyme Pharma, Inc.

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $161M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

More about INZY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Inozyme Pharma, Inc. Transaction History